This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Glaukos’s 8K filing here.
About Glaukos
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Read More
- Five stocks we like better than Glaukos
- Where Do I Find 52-Week Highs and Lows?
- Guidewire Software Provides Long-Awaited Buying Opportunity
- Insider Trades May Not Tell You What You Think
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- What Investors Need to Know About Upcoming IPOs
- Fast-Growing Companies That Are Still Undervalued
